Healthcare Associated Infections (HAI)

Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.

The FDA has approved Firvanq for the treatment of C. diff-associated diarrhea and enterocolitis caused by Staphylococcus aureus.

Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention.

Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.

Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Richard Haupt, MD, MPH, discusses what is needed to ensure that a future C. diff vaccine is adequately stocked and delivered to wherever individuals show up for vaccination.

SHEA has released expert guidance advising hospitals on when they can safely take patients with multidrug-resistant bacteria off of contact precautions.

Marin H. Kollef, MD, discusses the mortality and health care costs associated with Pseudomonas infections.

A recent study compares the effectiveness of a novel fidaxomicin therapy with vancomycin for the treatment of C. difficile.

Edmond Hooker, MD, DrPH, discusses the cost benefit of investing in launderable hospital mattress covers to prevent CDIs.

In case you missed them, we've compiled the top 5 articles from this past week.

Dr. Richard Vickers, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.

Richard Haupt, MD, MPH, discusses what would be required to adequately implement the delivery of a future C. diff vaccine.

Patients in intensive care units are at greater risk of acquiring antimicrobial-resistant infections, and now, a group of international infectious disease experts ar calling for better protection for these high-risk patients.

The development of mold-active azoles has led to enormous advancements in both prevention and treatment of invasive fungal infections.

Dr. Richard Vickers, explains how antibiotics used to treat C. diff also damage the microbiome.

At the 5th annual international C. diff Awareness Conference and Health Expo, Dr. Edmond Hooker discussed an underreported problem in health care facilities everywhere.

Edmond Hooker, MD, DrPH, discusses the use of a launderable mattress cover to reduce C. diff rates in hospitals.

Intra-abdominal infections (IAIs) are defined as disease processes occurring in normally-sterile parts of the abdominal cavity, and are generally treated mechanically, such as by surgery.

Richard Haupt, MD, MPH, sheds light on the Clostridium difficile Vaccine Efficacy Trial (CLOVER).

Daniel Diekema, MD, explains how clinicians can actively work to prevent pathogen spread in their health care facilities.

A recent webinar hosted by the Centers for Disease Control and Prevention and nursing organizations highlighted the important role of nurses in implementing hospital antibiotic stewardship programs.

Dr. Richard Vickers, explains what makes ridinilazole unique.